Data Readout

Cerus's RedeS Phase 3 nears results after enrollment closed on schedule

The pathogen-reduction trial that took nine years to fill its 692-patient target now heads toward a second-half 2026 readout that will decide the PMA path for INTERCEPT RBCs.

By AppliedXLJuly 13, 2026Trial NCT03037164

Executive Summary

Cerus has finished enrolling its second pivotal U.S. trial for a pathogen-reduction technology meant to make transfused red blood cells safer, and the primary result is now the gating fact for the company's regulatory filing.
After years of shifting completion dates, the trial's most recent guidance proved accurate: enrollment closed and the study moved to its non-recruiting phase on schedule, which shifts the open question from execution to the data itself.
The result feeds directly into a modular premarket approval submission the company has told regulators depends on this trial's completion, making the readout a regulatory input, not just a scientific one.
No other trial in the competitive field shares this pathogen-inactivation approach in red-cell transfusion support, so the result will be read against the trial's own design rather than against a comparable prior readout.

The trial

RedeS (NCT03037164) is a Phase 3, registrational study testing red blood cells treated with the INTERCEPT Blood System, a pathogen-inactivation technology, against the standard of care in patients requiring transfusion for acute and chronic anemia. The trial's primary outcome measure is adjusted hemoglobin increment. Cerus disclosed on November 6, 2025 that it had completed enrollment in the trial, describing it as the second pivotal U.S. Phase 3 study of the INTERCEPT RBC system, and said results are expected in the second half of 2026. William Greenman, Cerus' president and chief executive officer, said the company continues "to make great strides in improving the safety and availability of transfused blood components around the globe". NCT03037164+1

The timeline arc

The trial started on May 11, 2017, and its primary completion date moved four times over the following years: from June 2020 to December 2021, then to December 2022, then to October 2025, before settling at July 31, 2026 in the November 2025 update. Enrollment targets also shifted, rising from 600 to 800 patients in March 2022 before the final enrolled count settled at 692 in November 2025. The trial briefly moved to a Withheld status for two days in October 2020 before reverting to Recruiting. The most recent guided window, tying the October 2025 completion date to the July 2026 date, held: the trial reached Active, not recruiting status with enrollment complete on November 10, 2025, matching its most recent target. NCT03037164

The regulatory tie

Cerus has told regulators it plans a modular premarket approval (PMA) submission incorporating results from RedeS alongside its companion trial ReCePI, with the final module expected to follow RedeS completion. The submission is explicitly conditional on the trial finishing. That structure means the RedeS readout is not an isolated data point: it is the fact the company has said will trigger the last piece of its FDA filing for the INTERCEPT RBC system.

Competitive isolation

No trial in the competitive field for red blood cell transfusion support shares INTERCEPT's pathogen-inactivation mechanism. The nearest identified comparator, Amustaline, tested in a Swiss Transfusion SRC trial, uses a different modality and target and sits outside this trial's mechanism class. Cerus' own related program, an INTERCEPT RBC trial in cardiac surgery patients (NCT03459287), completed in September 2024 with an adverse-events outcome measure, giving the company one internal precedent for how the pathogen-reduction platform has read out in a different surgical population.

This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.